Search

A clinical trial, NCT06578702, is being conducted at the University Hospital in Strasbourg, France to evaluate the effectiveness and safety of intermittent triple therapy for people living with HIV. This strategy has been validated in France through a randomized clinical trial called QUATUOR, but there is limited real-life data and it is not recommended internationally. The trial aims to improve knowledge on the efficacy and tolerance of this therapeutic strategy. The trial is currently recruiting participants and is expected to be completed by February 2025. [Extracted from the article]

A new study conducted by researchers at the University of South Africa explores the experiences of healthcare practitioners in managing HIV among young people in Namibia. The study found that there are low viral load suppression rates among older adolescents and young adults with HIV in Namibia, which poses a global challenge. Healthcare providers struggle to manage these age groups due to their unique demographic characteristics. The study highlights the need for improved knowledge among healthcare practitioners regarding viral load management and suggests strategies such as differentiated service delivery, interprofessional collaboration, and psychosocial support to address this issue and improve health outcomes for this population. [Extracted from the article]

A new study conducted by Florida International University explores the use of mHealth applications to improve treatment adherence and overall well-being in sexual minority men (SMM) with HIV. The study, called Supporting Treatment Adherence for Resilience and Thriving (START), is a randomized controlled trial that integrates positive affect regulation skills with self-monitoring of adherence and mood. The primary outcome of the study is detectable HIV viral load, and secondary outcomes include stimulant use severity, anti-retroviral therapy adherence, and positive affect. The research aims to recruit a national sample of up to 250 SMM with HIV who screen positive for stimulant use disorder and report suboptimal adherence. The study is ongoing and will provide valuable insights for future mHealth research in this population. [Extracted from the article]

A study conducted by researchers from Harvard T.H. Chan School of Public Health examined the clinical outcomes of postpartum women with HIV in Nigeria. The study evaluated antiretroviral therapy retention, adherence, and viral suppression among these women. The findings showed that 89.6% of women remained in care at 24 months, with 88.7% achieving viral suppression. Factors associated with loss to follow-up included a more recent HIV diagnosis, higher gravidity, fewer antenatal care visits, and a non-hospital delivery. The study suggests that longer follow-up time and inclusion of multiple facilities would be beneficial for future research. [Extracted from the article]

A study conducted at Asfendiyarov Kazakh National Medical University in Kazakhstan examined the cardiovascular contributors to cognitive impairment among people living with HIV aged 40 years and older. The study found that the Kazakh population has been aging, with noncommunicable diseases accounting for a majority of deaths. The researchers conducted a cross-sectional study among people living with HIV over the age of 40, collecting data on cardiovascular health, mental health, medical history, and HIV measures. The study found that further investigation is needed to understand the cardiovascular factors contributing to cognitive impairment among people living with HIV. [Extracted from the article]

A study conducted by Aix-Marseille University in France examined the impact of cannabidiol (CBD) on the health-related quality of life (HRQoL) of people living with HIV (PWH) who have undetectable viral loads. The study involved 80 participants who were randomly assigned to receive either a placebo or CBD treatment for 12 weeks, followed by a 4-week follow-up period. The researchers found that CBD had no significant effect on the overall HRQoL of the participants, but it did improve their physical functioning. Further research is needed to confirm these findings and explore the impact of CBD on PWH with lower baseline HRQoL. [Extracted from the article]

A recent study conducted by the Public Health Agency of Canada explores the association between different levels of suppressed viral load and the risk of sexual transmission of HIV among serodiscordant couples on antiretroviral therapy. The research aims to fill a gap in the literature by providing precise estimates of the risk of transmission at sustained viral load levels between 200 copies/mL and 1000 copies/mL. The study will involve a systematic review and meta-analysis, as well as the use of individual participant data. The findings will be disseminated through peer-reviewed publications, presentations, and conferences. [Extracted from the article]

A new study conducted by researchers at the University of Jaen explores the impact of HLA allele-KIR partners on sexually transmitted HIV-1 infection. The study found that the HLA/KIR system does not play a role in susceptibility to sexually transmitted HIV-1 infection. The research suggests that the genetics of HIV-1 viral load and disease progression are distinct from the genetics of HIV resistance. This information may be useful for individuals conducting research on HIV/AIDS and genetics. [Extracted from the article]

The article presents new research from Nitte (Deemed to be University) on the detection of high-risk human papillomavirus (HPV) in oesophageal carcinoma using real-time polymerase chain reaction (PCR). Topics discussed include the prevalence of HPV in oesophageal cancer, the challenges in detecting HPV due to variable assay results, and the need for further studies to clarify the clinical significance of HPV in the disease's development.

A patent application titled "Compositions And Methods For Debulking Virus Or Microorganism Load In The Oral Cavity" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors Henry Daniell and Robert P. Ricciardi, aims to address the need for compositions and methods that effectively reduce viral and microbial load in the oral cavity. The method involves orally administering a composition containing a trapping molecule that binds to proteins or glucans on the surface of viruses or microorganisms, thereby reducing their load in the oral cavity. The invention focuses on reducing transmission, recovery time, and complications associated with viral and microbial infections. The patent application specifically mentions the potential use of the method for reducing SARS-CoV-2 viral load. The inventors propose using chewing gum as a carrier for the composition. [Extracted from the article]

A recent study conducted by researchers at Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) in Germany has explored the role of the protein kinase pUL97 in cytomegalovirus (CMV) replication and pathogenesis. The study found that pUL97 interacts with host cyclins and CDKs, which are important for viral replication. This interaction presents potential targets for antiviral drugs. The researchers also discovered that inhibiting pUL97 and CDK7 simultaneously showed promising results in inhibiting CMV replication. This research provides new insights into the regulation of CMV and potential strategies for antiviral drug development. [Extracted from the article]

A clinical trial, NCT06572618, is currently underway to test the effectiveness of nemtabrutinib in combination with rituximab for the treatment of mantle cell lymphoma. Nemtabrutinib is a kinase inhibitor that targets a protein called BTK, which is found in B-cell cancers like mantle cell lymphoma. Rituximab is a monoclonal antibody that binds to a protein called CD20, potentially aiding the immune system in killing cancer cells. The trial aims to assess various outcomes, including response rates, survival rates, and duration of response, in patients receiving this combination therapy. Additionally, the document provides alternative names for medical procedures and drugs, such as bone marrow biopsies, Nemtabrutinib, positron emission tomography and computed tomography scans, and Rituximab. It also offers information about a clinical trial for Rituximab, which is not yet recruiting participants and plans to enroll 27 individuals. The trial is open to people of all genders aged 18 and above who have been diagnosed with mantle cell lymphoma and require treatment with no prior systemic anticancer therapies. The study is a collaboration between the City of Hope Medical Center and the National Cancer Institute. [Extracted from the article]

A study conducted at Gombe State University in Nigeria examined the medication-related burden and virological response of adults living with HIV/AIDS (PLHIV). The study involved 417 PLHIV who had been on antiretroviral therapy for at least a year. The majority of patients achieved viral suppression, but only 67.6% of the population experienced a moderate medication-related burden. Female sex, unsuppressed viral load, second-line antiretroviral therapy, tuberculosis at therapy initiation, and employment were significantly associated with medication-related burden. The study suggests that targeted interventions should focus on younger patients, females, and those with unsuppressed viral loads. [Extracted from the article]

A study conducted by researchers at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran in Mexico aimed to determine the effectiveness of switching to bictegravir in maintaining an undetectable viral load among people with HIV compared to continuing with dolutegravir, efavirenz, or raltegravir-based antiretroviral therapy. The study analyzed nationwide observational data from Mexico and found that switching to bictegravir was more effective in maintaining viral suppression than continuing with the other therapies. The study included over 3 million people with HIV and concluded that bictegravir may be a more effective treatment option. [Extracted from the article]

A systematic review conducted by researchers at Sri Manakula Vinayagar Medical College and Hospital in Puducherry, India, analyzed the efficacy and safety of ibalizumab for the treatment of HIV-1-infected patients. The review included four studies that examined the effects of ibalizumab on CD4 cell counts and viral load reduction. The results showed that patients who received a higher dose of ibalizumab experienced a significant increase in CD4+ T-cell count. However, the viral load reduction did not increase proportionately at doses beyond 10mg/kg. Common adverse effects of ibalizumab included headache, diarrhea, nausea, fatigue, somnolence, and rash. The researchers concluded that ibalizumab shows promise as a therapeutic option for individuals with multidrug-resistant HIV-1. [Extracted from the article]

A recent study conducted in Uganda examined the relationship between adherence to antiretroviral therapy (ART) and viral suppression in individuals with HIV/AIDS. The study found that under non-dolutegravir (DTG) regimens, viral suppression was significantly lower when adherence levels were between 0% and 79%. However, for participants taking DTG, there was no significant difference in viral suppression at any adherence level. The study suggests that DTG regimens may be more forgiving of missed doses and should be prioritized over older regimens, particularly for individuals with low adherence. [Extracted from the article]

A new report discusses research conducted at Hunan University of Arts and Science on the influence of cytokine-enhanced rate and antibody delay on viral infection in the context of HIV/AIDS. The researchers propose a model that includes multiple time delays, such as intracellular delay, virus replication delay, and antibody delay. The stability of the model's equilibria is investigated, and it is found that the antibody immune response delay can lead to stability switches and Hopf bifurcation. The theoretical results are supported by numerical simulations. This research provides insights into the dynamics of HIV infection and the impact of immune response delays. [Extracted from the article]

The article highlights research conducted by University Hospital Tuebingen on the implications of Parvovirus B19 in childhood myocarditis, emphasizing its impact on young patients. Topics discussed include the frequency of B19V infection in acute versus chronic myocarditis, the correlation between viral loads and immune response in children, and the importance of comprehensive histopathological and molecular analyses for timely diagnosis and treatment.

The article focuses on a phase II clinical trial evaluating the perioperative efficacy and safety of cardenilimab combined with lenvatinib for resectable clear cell renal cell carcinoma. It explains that the trial includes a screening, treatment, and follow-up period, assessing outcomes such as objective response rate, progression-free survival, and overall survival, while also monitoring adverse events and quality of life.

A recent study conducted by the Cusack group at EMBL Grenoble has provided new insights into how the avian influenza virus can mutate to replicate in mammalian cells. The study focused on the role of the polymerase enzyme in the replication process and discovered that a host cell protein called ANP32 acts as a bridge between the two viral polymerases. The study also found that the avian and mammalian versions of ANP32 differ, which explains why the avian influenza virus does not easily replicate in mammals and humans. These findings are important for understanding the potential for avian influenza to cross the species barrier and could aid in the development of anti-influenza drugs. [Extracted from the article]

A recent study conducted by researchers at Wayne State University School of Medicine has discovered two novel compounds, GL-287 and GL-382, that effectively inhibit the replication of the Zika virus in ocular cells. These compounds outperformed existing autophagy inhibitors and did not exhibit cytotoxicity in the cells. Additionally, GL-287 and GL-382 were found to suppress the Zika virus-induced inflammatory response in ocular cells. This research highlights the potential of these autophagy inhibitors as safe and potent antiviral treatments for Zika virus infections. [Extracted from the article]

A recent study conducted in Taiwan aimed to determine the extent to which intrahepatic and extrahepatic diseases contribute to mortality in individuals with Hepatitis C virus (HCV) infection. The study found that approximately 54.1% of HCV-induced mortality was mediated by intrahepatic diseases such as liver cirrhosis and liver cancer, while 45.9% was mediated by extrahepatic diseases. The major extrahepatic mediating diseases included septicemia, renal disease, blood/immune diseases, gallbladder diseases, and endocrine diseases. The study also demonstrated a dose-response relationship between HCV viral load and the mediation effect. Overall, both intrahepatic and extrahepatic manifestations mediated approximately half of HCV-induced mortality. [Extracted from the article]

A report from the University of Washington discusses research on biosensors and their role in understanding drug resistance in cancer cells. The study focused on the adaptive effects of Ras-G12C inhibitors on Ras signaling at the single-cell level. The researchers used Ras biosensors to analyze the activity and signaling environment of Ras in cancer cells and found that certain cells underwent adaptive signaling and metabolic changes in response to the drugs. The study identified major vault protein as a mediator of Ras activation and highlighted the importance of single-cell analysis in understanding drug resistance. [Extracted from the article]

New research from La Trobe University in Bundoora, Australia explores the mechanism behind the ability of HIV controllers to control viral replication and remain healthy. The study focuses on the HLA-B57:01 molecule, which is expressed by almost 50% of HIV controllers and presents the Gag-derived epitope TW10. The researchers found a bias in TCR gene usage and a public TCR in TW10-specific T cells, indicating their potential role in controlling HIV. The study also provides the crystal structure of HLA-B57:01-TW10 in complex with a TCR, shedding light on the recognition process. [Extracted from the article]

A study conducted at the Christian Medical College and Hospital in Tamil Nadu, India, examined the prevalence and impact of Human Pegivirus-1 (HPgV-1) on individuals living with HIV (PLHIV). The study found that HPgV-1 viremia was present in 11% of PLHIV and 1% of controls. The predominant genotype of HPgV-1 was 2a in PLHIV and 2b in controls. The study also found a correlation between HPgV-1 viral load and CD4+ T-cell count, as well as an inverse correlation with HIV-1 viral load. The researchers concluded that further longitudinal studies are needed to understand the potential impact of HPgV-1 on HIV-1 disease progression. [Extracted from the article]

A new study conducted by researchers at Northwestern University Feinberg School of Medicine explores the barriers and suggestions for improving viral load testing (VLT) uptake in Tanzania. The study found that only 58% of patients in Tanzania receive VLT annually, which is contrary to the Tanzanian National Guidelines. The primary individual barrier to VLT uptake was missing appointments, along with limited knowledge among individuals living with HIV. System-level barriers, such as a lack of integrated care and evening service availability, were also identified. The study suggests that there is potential for improvement in the uptake and quality of VLT services in Tanzanian public health facilities through a holistic approach. [Extracted from the article]

A recent study conducted by the State University of New York (SUNY) explores the challenges and opportunities of at-home blood collection for HIV-1 viral load monitoring among sexually minoritized men who use stimulants. The study found that home-based viral load monitoring could support interim, early identification of detectable viral loads, which is important for HIV care. The research involved recruiting participants who reported moderate-to-severe stimulant use disorder and suboptimal antiretroviral therapy adherence. The study concluded that while home blood collection using the HemaSpot-HD device was feasible, building rapport through teleconferencing and providing detailed instructions could strengthen interim viral load monitoring for individuals experiencing difficulties with antiretroviral therapy adherence. [Extracted from the article]

A clinical trial, NCT06562543, is being conducted to assess the safety and effectiveness of oral fruquintinib in treating refractory metastatic colorectal cancer (mCRC) in minority populations. The trial aims to determine the occurrence of hypertension in minority groups, such as Black/African American and Hispanic/Latino, after receiving fruquintinib treatment. Participants will receive fruquintinib in 4-week cycles until their condition worsens or they can no longer tolerate the treatment. The trial will also evaluate the safety and tolerability of fruquintinib. The study is not yet recruiting and is expected to be completed by February 18, 2028. [Extracted from the article]

This document provides information about a clinical trial in China for the treatment of locally advanced gastric cancer. The trial aims to explore the effectiveness and safety of combining sintilimab, chemotherapy, and radiotherapy for elderly patients. The trial is currently recruiting participants and is expected to be completed by December 31, 2026. The document outlines the specific treatment plan, eligibility criteria, and various outcomes that will be assessed. [Extracted from the article]